Source: Eur Respir J 2014; 44: 1011-1022
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Kim Lucia, Tsao Ming Sound. Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?. Eur Respir J 2014; 44: 1011-1022

Member's Comments

No comment yet.

Related content which might interest you: Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Tissue is the issue and beyond: proper sampling for diagnosis and staging of lung cancer by chest physicians as well as its alternatives Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Modern profiling of advanced lung cancer at the primary diagnosis and during therapy Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 The clinical benefit of personalised medicine in lung cancer Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014 Precision medicine for lung cancer: new targeted treatments  Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017 Modern molecular lung cancer diagnostics – how to use and interpret it wisely Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Eminence or evidence based ? – personalised diagnostic-therapeutic sequences in a molecular altered advanced NSCLC patient Source: International Congress 2017 – GR2 Lung Cancer Grand Round Year: 2017 Challenges in molecular testing in lung cancer patients with advanced disease Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Slow-growing lung cancer as an emerging entity: from screening to clinical management Source: Eur Respir J 2013; 42: 1706-1722 Year: 2013 Evolution in the diagnostic approach to lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Lung cancer, noninvasive molecular treatment and monitoring Source: International Congress 2016 – ERS-ALAT-SBPT-SEPAR-SPP joint session: Spanish and Portuguese Session II Year: 2016 Is EBUS sampling adequate for molecular testing in patients with advanced NSCLC? Source: Virtual Congress 2020 – Current and contemporary practices in endobronchial ultrasound Year: 2020 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 PG1 Re-defining the role of chest physicians in lung cancer:ÿnew opportunities in diagnostics and therapy Source: Milan 2017 - Educational material Year: 2017 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014